Chimerix to Join Fireside Chat at Jefferies Healthcare Conference

Chimerix, a biopharmaceutical company headquartered in Durham, North Carolina, has announced that its CEO, Mike Andriole, will be participating in the Jefferies Global Healthcare Conference. This event is scheduled for Thursday, June 6, 2024, at 3:00 p.m. Eastern Time. During this conference, Andriole will engage in a fireside chat, discussing the company's ongoing efforts and strategic direction.

For those unable to attend in person, an audio webcast of the discussion will be made available. Interested parties can access this webcast through the Investor Relations section of Chimerix's website. The recording will remain accessible for approximately 90 days after the event, allowing stakeholders to listen to the detailed insights shared during the session.

Chimerix is committed to developing innovative medicines aimed at significantly improving and prolonging the lives of patients battling severe illnesses. Among its various projects, the company's leading clinical-stage development is ONC201. This promising drug is currently being developed to treat H3 K27M-mutant glioma, a particularly aggressive form of brain cancer.

The company's dedication to advancing medical treatments underscores its mission to address unmet medical needs. By participating in the Jefferies Global Healthcare Conference, Chimerix aims to communicate its progress and future plans to investors, medical professionals, and other stakeholders.

The participation of Chimerix in such high-profile industry conferences highlights its proactive approach in the biopharmaceutical sector. This engagement not only serves to update current investors but also attracts potential new investors by showcasing the company's ongoing commitment to innovative healthcare solutions.